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Heart failureThe natriuretic peptide system exerts beneficial car-
diorenal effects in chronic heart failure, whereas acti-
vation of the renin–angiotensin–aldosterone system
exerts opposing and deleterious effects. LCZ696, a
first-in-class angiotensin receptor neprilysin inhibitor,
targets both neurohormonal systems by inhibiting
neprilysin, which prevents natriuretic peptide degrada-
tion, while concomitantly blocking the angiotensin
(AT1) receptor. In clinical studies of patients with
chronic heart failure with reduced and preserved left
ventricular ejection fraction, LCZ696 has been shown
to improve biomarkers of cardiorenal function. The
effects of LCZ696 on cardiovascular outcomes and
survival in patients with heart failure are currently
being investigated.        
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Introduction
Heart failure (HF) is a common syndrome, resulting in high
mortality. The prevalence of HF has risen steadily in recent
years and this trend is expected to continue due to a growing
aging population with more cardiovascular risk factors [1,2].
Indeed, risk factors, such as hypertension, are common prog-
nostic comorbidities in chronic HF [3].
The impact of HF on patient quality of life and the financial
burden imposed on the healthcare system are great, with
frequent costly hospitalizations and a 5-year mortality rate of
approximately 50% [2]. While survival rates have improved
for HF with reduced ejection fraction (HFrEF) due to more
widespread use of drugs that block the renin–angiotensin–
aldosterone system (RAAS) residual mortality rates remain
high. For patients with HF with preserved ejection fraction
(HFpEF) no therapy has proven to be effective at reducing
morbidity and mortality [4]. Consequently, there is an urgent
need for new therapies to prevent and treat HFrEF and HFpEF.
Role of the RAAS and natriuretic peptides (NPs) in heart failure
The consequences of activation of the RAAS and sympathetic
nervous system in the pathogenesis of HF are well established,
as is the therapeutic benefit of RAAS blockers in improving HFhttp://dx.doi.org/10.1016/j.ddstr.2013.11.002 e131
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evidence indicates that the natriuretic peptide (NP) system,
which mediates beneficial cardiorenal effects, is also impaired
in HF [5]. This suggests that approaches designed to upregu-
late NPs and/or enhance their biological activity may be of
therapeutic benefit, particularly in conjunction with RAAS
blockade [5].
The RAAS and HF
Chronic HF is a progressive condition characterized by ele-
vated cardiac filling pressures, reduced cardiac output and
decreased tissue oxygen delivery [6]. These hemodynamic
abnormalities result in activation of the RAAS and sympa-
thetic nervous system to maintain vital organ perfusion [6].
Initially, this serves as an acute compensatory response, but
prolonged activation contributes to the pathophysiology of
HF, resulting in progressive cardiorenal abnormalities,
including myocardial hypertrophy, fibrosis and apoptosis,
increased systemic vascular resistance, and increased sodium
and water retention [6,7].
The NP system and HF
The NP system comprises three structurally similar peptides
with cardiorenal protective properties: atrial NP (ANP), B-type
NP (BNP) and C-type NP (CNP) [8]. ANP and BNP are pri-
marily expressed in the heart and released by cardiomyocytes
in response to mechanical stretch [5]. CNP is derived mainly
from endothelial and renal cells and secreted in response to
endothelium-dependent agonists and pro-inflammatory
cytokines [5]. As filling pressures rise in HF, increased cardiac
stretch causes the secretion of precursor NPs, which are
cleaved by specific proteases to produce biologically active
NPs which then act on NP receptors (NP receptor-A [NPR-A],
NPR-B and NPR-C) [8]. Binding of NPs to NPR-A and NPR-B
activates particulate guanylate cyclase resulting in increases
in the second messenger, cyclic guanosine monophosphate
(cGMP), which mediates many of the cardiovascular and
renal effects of the NPs [8,9].
NPs are cleared from the circulation by two mechanisms –
binding to NPR-C and inactivation (hydrolytic cleavage) by
neprilysin [8]. Neprilysin has a high affinity for both ANP and
CNP, and a lower affinity for BNP, which is more resistant to
hydrolysis [10]. Since neprilysin does not hydrolyze N-term-
inal pro-BNP (NT-proBNP) [11], it remains a useful cardiac
biomarker to assess therapeutic effect and prognosis in
patients treated with neprilysin inhibitors.
The cardiovascular and renal effects of the NP system
oppose those of the RAAS [12], providing the scientific and
therapeutic basis for neprilysin inhibition in the setting of
HF. One of the major effects of NPs is vasodilation, which
results from cGMP-mediated relaxation of smooth muscle
cells as well as indirect effects of NPs to inhibit the RAAS and
decrease endothelin-1 (ET-1) production [9]. Indeed, NPse132 www.drugdiscoverytoday.comhave been shown to cause significant reductions in systemic
vascular resistance, pulmonary artery pressure, pulmonary
capillary wedge pressure and right arterial pressure in patients
with severe HF [13]. NPs also mediate other beneficial hemo-
dynamic effects, including reducing arterial stiffness and
enhancing endothelial function [14].
NPs promote sodium and water excretion by inhibiting
sodium reabsorption in the proximal and distal nephron,
while preventing decreases in glomerular filtration rate by
regulating tubuloglomerular feedback [9]. These effects of
NPs have been observed in patients with severe HF, resulting
in improvement in hemodynamics and renal function [13].
In addition to the direct effects of NPs on the kidney, their
inhibitory actions on the RAAS and sympathetic nervous
system also contribute to their natriuretic, diuretic and
hemodynamic effects [9,14].
The NPs have potent cardiac antihypertrophic and anti-
fibrotic properties. In animal models, ANP and CNP inhibit
cardiac hypertrophy induced by angiotensin II (Ang II) or ET-
1 [15,16]. Furthermore, in cardiac fibroblasts, ANP and BNP
inhibit the fibrotic effects of transforming growth factor beta
(TGF-b), while Ang II-induced interstitial fibrosis was inhib-
ited by CNP [16].
Recent experimental and clinical data indicate that NPs
have physiologically important metabolic effects that may be
relevant to HF [17,18]. ANP has been shown to stimulate
lipolysis in human adipocytes by activating the NPR-A recep-
tor and increasing intracellular cGMP [19]. ANP-induced
lipolysis could contribute to cardiac energy utilization by
providing substrate in the form of free fatty acids and pro-
moting lipid oxidation through increased mitochondrial
biogenesis [17,20]. On the other hand, an imbalance between
fatty acid uptake and utilization for adenosine triphosphate
(ATP) generation could result in mitochondrial oxidative
stress and lead to excessive cardiomyocyte accumulation of
neutral lipids, contractile dysfunction and lipotoxicity [21].
Other metabolic effects of NPs demonstrated in human tissue
samples include increased oxygen consumption and
enhanced expression of adiponectin. Studies in animal and
human adipocytes have also shown that NPs induce brown
fat thermogenesis and can mediate a phenotypic switch from
white to brown fat [17]. Furthermore, there is emerging
evidence that NP signaling may directly improve glucose
control and inhibit adipocyte growth [17,18,22]. Finally, a
specific human ANP genetic polymorphism which increases
circulating ANP has been reported to protect against hyper-
tension and metabolic syndrome [23]. The relevance of the
metabolic effects of NP to insulin resistance and cardiovas-
cular diseases is an active area of research.
Dysregulation of the NP system and role of neprilysin in HF
While it was initially thought that the NP system was
upregulated in HF due to high circulating levels of total
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mature BNP (BNP1–32) levels are reduced and levels of less
biologically active BNP fragments are increased [5]. This is
due to altered processing of proBNP to biologically active
BNP1–32 [24] and partly explains the blunting of the phy-
siological response to high levels of total immunoreactive
BNP observed in patients with HF [5]. Thus, advanced HF may
represent a state of NP deficiency [5]. Furthermore, the
expression and activation of neprilysin are increased in
patients with HF, which enhances the rate of degradation
of NPs and contributes to reduced levels of biologically active
NPs [25].
As HF progresses, relative resistance or hyporesponsiveness
to NPs develops, which is particularly evident in the kidney
and vasculature [8,12]. This hyporesponsiveness is an impor-
tant feature of HF that adversely affects prognosis by worsen-
ing sodium retention and volume overload and increasing
peripheral vascular resistance. The mechanisms for NP resis-
tance are multifactorial and include: downregulation of NP
receptors, dysregulated NP signal transduction, increased
cGMP degradation and activation of the RAAS [26].
In addition to hydrolyzing the NPs, neprilysin also hydro-
lyzes other vasoactive peptides, including substance P, bra-
dykinin, ET-1, angiotensin I (Ang I) and Ang II [27,28]. Since
there are multiple neprilysin substrates with differing and, in
some instances, opposing biologic actions, the pharmacolo-
gic profile of neprilysin inhibitors is complex and will depend
on the net effect on all biologically relevant substrates. While
inhibition of neprilysin is expected to result in beneficial
cardiovascular and renal effects in HF by increasing NP levels,
corresponding increases in Ang II and ET-1, both of which
have vasoconstrictor, pro-fibrotic and pro-hypertrophic
properties, would be expected to oppose the beneficial effects
of the NPs. In the case of angiotensin, neprilysin hydrolyzes
and inactivates Ang II; therefore, neprilysin inhibition alone
will not only increase NP levels but can also result in accu-
mulation of Ang II, which could attenuate or negate any
beneficial NP effects in the setting of HF. The increase in Ang
II observed with neprilysin inhibition provides a rationale for
concomitant RAAS blockade. However, neprilysin also con-
verts Ang I to Ang 1–7 [28], which has vasodilating, anti-
proliferative and natriuretic actions mediated through
activation of the Mas receptor [29]. In the case of ET-1,
neprilysin not only hydrolyzes ET-1, but also its precursor
peptide big ET-1. Thus, the effect of a neprilysin inhibitor on
ET-1 levels will depend on the net effect of hydrolysis of both
big-ET1 and ET-1 [27]. It should also be noted that both
substance P and bradykinin, which are both inactivated by
neprilysin, have vasodilatory properties, increase vascular
permeability and, when combined with an angiotensin-
converting-enzyme inhibitor (ACEI), are implicated in the
pathogenesis of angioedema [30], a potential side effect of
neprilysin inhibitors.NPs as treatment for chronic HF
The therapeutic rationale for the initial development of
neprilysin inhibitors as a potential treatment for chronic
HF is based on the observation that neprilysin inhibition
increases endogenous NP levels [31,32]. One of the first
selective neprilysin inhibitors studied in humans was can-
doxatril, which produced beneficial hemodynamic, natriure-
tic and diuretic effects in patients with chronic HF [32,33]. In
patients with chronic HF receiving ACEI, candoxatril also
improved exercise tolerance compared with placebo [34].
However, as noted above, neprilysin also degrades Ang II;
therefore, neprilysin inhibition also activates Ang II-depen-
dent pathways [31], limiting the utility of selective neprilysin
inhibitors as monotherapy for HF. Activation of the RAAS
attenuates the actions of NPs and RAAS inhibition has been
reported to potentiate the effects of neprilysin inhibition in a
canine model of HF [35]. Therefore, achieving the potential
clinical benefits of neprilysin inhibition will likely require
concomitant inhibition of the RAAS.
These observations led to the therapeutic strategy of con-
comitant inhibition of neprilysin and the angiotensin-con-
verting enzyme (ACE), and to the development of
omapatrilat. In a Phase III trial in patients with chronic
HF, omapatrilat demonstrated a trend towards improved
morbidity and mortality with once daily dosing that might
have been even greater with a more frequent dosing regimen
[36]. However, omapatrilat treatment was also associated
with a substantially increased risk of angioedema [36], and
its development was discontinued.
Angioedema is thought to be mediated by increases in
bradykinin, des-Arg9-bradykinin and possibly substance P,
potent vasoactive peptides that cause vasodilation and
enhance vascular permeability [30]. Bradykinin is degraded
predominantly by ACE, but also by aminopeptidase P (APP),
neprilysin and dipeptidyl peptidase 4 (DPP-4) [37]. Compared
with ACE and aminopeptidase P, the relative contribution of
neprilysin to the degradation of substance P and bradykinin
appears to be very small [37]. In the presence of ACE inhibi-
tion, the development of angioedema is believed to require
functional (genetic or pharmacologic) defects in several non-
kininase II enzymatic pathways [30,38]. Omapatrilat not only
inhibits ACE, but also inhibits APP and neprilysin. The
increase in bradykinin resulting from inhibition of all three
enzymes may have been the cause of the increased incidence
of angioedema observed with that agent [37].
The therapeutic strategy of concomitant neprilysin and
RAAS inhibition still holds promise for patients with chronic
HF assuming the risk of angioedema can be minimized while
achieving superior efficacy compared to RAAS blockers alone.
While angiotensin type 1 (AT1) receptor blockers (ARBs) are
known to cause angioedema, the reported incidence is much
less than that for ACEIs [39]. The proposed mechanism for
ARB induced angioedema involves Ang-II/AT2 receptorwww.drugdiscoverytoday.com e133
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bitory effects on ACE and possibly neprilysin [40]. Thus, a
potentially more successful therapeutic strategy would be to
block the RAAS at the AT1 receptor rather than inhibit ACE.
Experiments in stroke-prone spontaneously hypertensive rats
have shown that concomitant neprilysin inhibition and AT1
receptor blockade improved endothelial function to a similar
extent as that achieved with combined neprilysin and ACE
inhibition [41]. In an in vitro study in rat cardiomyocytes and
fibroblasts, simultaneous addition of a neprilysin inhibitor
and ARB into the culture media was more effective than the
ARB alone in inhibiting biochemical markers of cardiac
hypertrophy and fibrosis [42]. Finally, an in vivo study in
spontaneously hypertensive rats found that concomitant
neprilysin inhibition and angiotensin receptor blockade low-
ered blood pressure (BP) to a similar extent as neprilysin-ACE
inhibition with omapatrilat, but had no effect on trachealNP systemPhysiological
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upper airway angioedema), whereas neprilysin-ACE inhibi-
tion with omapatrilat increased tracheal plasma extravasa-
tion [43]. These experimental data highlight the potential for
concomitant neprilysin inhibition and AT1 receptor blockade
for producing beneficial cardiovascular effects without
increasing the risk of angioedema.
LCZ696, a novel angiotensin receptor neprilysin
inhibitor (ARNI): pharmacological profile,
experimental and clinical results
ARNIs represent a novel class of drugs being developed for the
treatment of HF whose multimodal mode of action involves
neprilysin inhibition and AT1 receptor blockade. ARNIs
enhance the beneficial physiological response of NPs while
blocking the harmful effects of RAAS activation (Fig. 1).Ne
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ulate two counter-regulatory neurohormonal systems in HF: the renin–
G: angiotensin; ARNI: angiotensin receptor neprilysin inhibitors; AT1:
iphosphate; HF: heart failure; NP: natriuretic peptide (e.g. atrial natriuretic
; RAAS: renin–angiotensin–aldosterone system; zIn vitro evidence.
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LCZ696 is the first in class ARNI in clinical development.
LCZ696 is a new chemical entity comprising anionic moieties
of the neprilysin inhibitor prodrug AHU377 and the ARB
valsartan [44]. Oral administration of LCZ696 provides con-
comitant systemic exposure to AHU377, which is metabo-
lized to the active neprilysin inhibitor LBQ657, and valsartan
[45].
The pharmacokinetics of LCZ696 have been well charac-
terized. Oral administration of single and multiple ascending
doses of LCZ696 to 41 healthy volunteers resulted in rapid,
approximately dose proportional systemic exposure to both
the ARB and neprilysin inhibitor moieties of LCZ696 [45].
Following multiple dose administration, the systemic expo-
sures of valsartan and the active neprilysin inhibitor LBQ657
occurred rapidly, with maximum plasma concentration
(Cmax) for valsartan achieved within 1.6–4.9 hours, and for
LBQ657 within 1.8–2.7 hours [45].
Experimental studies have demonstrated that LCZ696
inhibits both neprilysin and the RAAS. Sprague–Dawley rats
infused with ANP (450 ng/kg/min) exhibited a dose-depen-
dent augmentation of plasma ANP immunoreactivity in
response to LCZ696, indicating neprilysin inhibition
(Fig. 2). The antihypertensive effects of LCZ696 were stu-
died in conscious chronically instrumented double trans-
genic rats expressing the genes for human renin and
angiotensinogen [45]. In this model of Ang-II-induced
hypertension, oral administration of LCZ696 resulted in a
dose-dependent and long-lasting reduction in mean arterial
pressure (Fig. 2).8-
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Figure 2. Effect of oral administration of LCZ696 on (a) change from baseline 
Dawley rats (n = 4) infused with ANP (450 ng/kg/min); (b) change in mean art
overexpressing human renin and angiotensin and exhibiting angiotensin II-depe
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Wiley & Sons, Inc. Copyright 2010 John Wiley & Sons, Inc.A study in healthy human subjects confirmed that LCZ696
provides concurrent neprilysin inhibition and AT1 receptor
blockade [45]. Following multiple dose administration of
LCZ696, 24-hour mean plasma cGMP (the NP effector signal-
ing messenger) was increased compared with placebo, which
is consistent with neprilysin inhibition. Dose-dependent
increases in plasma cGMP compared with placebo were
observed as early as 4 hours post-dose, with levels returning
to baseline by 24 hours (Fig. 3; [45]). LCZ696 also resulted in
dose-dependent increases in plasma renin concentration,
plasma renin activity (PRA) and Ang II levels, which is con-
sistent with AT1 receptor blockade (Fig. 3; [45]). The max-
imum concentrations of the RAAS biomarkers were reached
by 4 hours after administration of multiple doses of LCZ696.
Furthermore, the sustained pharmacodynamic effects follow-
ing LCZ696 administration, together with the long observed
plasma t1/2 for both valsartan and LBQ657, indicate the
suitability of LCZ696 for once- or twice-daily dosing.
LCZ696 pharmacodynamics, clinical efficacy and safety in patients
with hypertension
A study in patients with hypertension (mean systolic BP
139.6  9.2 (standard error) mmHg at baseline) has examined
the effect of LCZ696 compared with valsartan on natriuresis,
diuresis and urinary cGMP [46]. LCZ696 (400 mg once daily
for 7 days) was associated with increases in natriuresis,
diuresis and fractional sodium excretion compared with
valsartan. For each of these measures, the natriuretic
effect of LCZ696 was greatest on the first day of drug
administration and diminished with continued dosing, likelyVehicle 2 6 20 60
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in plasma atrial natriuretic peptide immunoreactivity (ANPir) in Sprague-
erial pressure (DMAP) in double-transgenic rats (dTGR) (n = 6)
ndent hypertension [45]. ANP: atrial natriuretic peptide; ANPir: atrial
n arterial pressure. This material is reproduced with permission of John
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Figure 3. Effect of oral administration of LCZ696 200 mg on (a)
geometric mean change in plasma cGMP; (b) renin concentration; (c)
plasma renin activity; (d) angiotensin II in healthy volunteers (n = 42)
[45]. NB: In this dose-escalation study, patients received multiple
doses of LCZ696 (50, 200, 600 and 900 mg). Data shown are for the
200 mg dose, which gave the greatest increase in cGMP. *p < 0.05
versus placebo. cGMP: cyclic guanosine monophosphate.due to counter-regulatory mechanisms in response to the
cumulative negative sodium balance. The study also showed
that LCZ696 provided sustained neprilysin inhibition as
indicated by increased urinary cGMP excretion throughout
the study [46]. Treatment with LCZ696 in this study was
further associated with larger reductions in both systolic
BP and diastolic BP compared with valsartan. The clinical
efficacy of LCZ696 has also been studied in a randomized,
double-blind, placebo-controlled study in 1328 patients with
mild-to-moderate hypertension [47]. LCZ96 (200 and
400 mg) provided significantly greater BP reductions than
comparable exposure to valsartan (160 mg and 320 mg,
respectively). LCZ696 was well tolerated, with no reported
cases of angioedema and no serious adverse events judged to
be related to LCZ696 [47]. A study in Asian patients with
mild-to-moderate hypertension has confirmed the BP-low-
ering effect and favorable safety profile of LCZ696 [48].e136 www.drugdiscoverytoday.comLCZ696 pharmacodynamics, clinical efficacy and safety in patients
with HFrEF
LCZ696 has been studied in patients with HFrEF. In an open-
label, non-controlled study of 30 patients with stable chronic
HF and left ventricular ejection fraction (LVEF) 40%,
LCZ696 100 mg titrated to 200 mg twice daily was shown
to increase plasma cGMP and urinary ANP after 7 and 21 days
of drug administration, confirming inhibition of neprilysin
[49]. Furthermore, administration of LCZ696 led to signifi-
cant increases in PRA and plasma renin concentration, indi-
cative of AT1 receptor blockade. In addition, plasma
aldosterone and ET-1 levels were reduced, confirming clini-
cally relevant RAAS inhibition [50]. Importantly, LCZ696
significantly decreased plasma NT-proBNP (p < 0.001) [49].
No serious adverse events occurred during the study. These
effects support further studies of LCZ696 in chronic HF.
LCZ696 is currently being investigated in the Prospective
comparison of ARNI with ACEI to Determine Impact on
Global Mortality and morbidity in Heart Failure trial (PARA-
DIGM-HF), a Phase III randomized, double-blind, parallel-
group study comparing the long-term safety and efficacy of
LCZ696 versus enalapril in patients with chronic HF and
reduced LVEF (40%). The primary endpoint is the compo-
site of cardiovascular death or HF hospitalization. The sec-
ondary endpoints include assessment of changes in HF
symptoms, physical limitations on quality of life, new onset
of atrial fibrillation, and development/progression of renal
dysfunction [51]. PARADIGM-HF is an event-driven trial and,
as of January 17, 2013, the study is fully enrolled, with 8436
randomized patients at 985 centers in 47 countries [51].
LCZ696 pharmacodynamics, clinical efficacy and safety in patients
with HFpEF
LCZ696 has also been investigated in patients with HFpEF.
HFpEF is characterized by abnormal left ventricular diastolic
function with associated increases in ventricular filling pres-
sures, increased vascular stiffness and impairments in systolic
function despite preserved ejection fraction [52]. HFpEF is
associated with an impaired NP response and renal endocrine
response to volume overload [52]. As a result, it is hypothe-
sized that LCZ696, by augmenting the effects of NPs, would
be of clinical benefit in these patients.
PARAMOUNT was a Phase II, randomized, double-blind
multicenter trial in patients with HFpEF (LVEF 45%) [52].
The primary endpoint was change from baseline to Week 12
in levels of NT-proBNP [52], a marker of left ventricular wall
stress that is associated with adverse outcomes in patients
with HFpEF [53]. Patients were randomized to receive LCZ696
200 mg twice daily or valsartan 160 mg twice daily (dose
equivalent) for 36 weeks. At 12 weeks, LCZ696 reduced NT-
proBNP from baseline by 23% compared with valsartan
(p = 0.005; Fig. 4). PARAMOUNT also assessed the effect of
LCZ696 on left atrial structure and function by measuring left
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Figure 4. Effect of LCZ696 200 mg twice daily versus valsartan 160 mg twice daily (dose equivalent) in patients with chronic HF with preserved ejection
fraction (NYHA class II–III, LVEF 45%, NT-proBNP >400 pg/mL). (a) NT-proBNP concentration (pg/mL) (geometric mean [95% CI]); (b) left atrial width,
volume and volume index (mean SD) [52]. *p = 0.005; #p < 0.01 versus valsartan. CI: confidence interval; HF: heart failure; LVEF: left ventricular ejection
fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; NYHA: New York Heart Association; SD: standard deviation.atrial width, volume and volume index [52], parameters that
have been shown to be predictors of outcome in chronic HF,
with and without reduced LVEF [54,55]. After 36 weeks of
treatment, left atrial width, volume, and volume index were
significantly reduced from baseline to a greater extent with
LCZ696 compared with valsartan (Fig. 4). LCZ696 was also
shown to have beneficial effects on renal function, with
smaller mean decreases in estimated glomerular filtration
rate from baseline compared with valsartan (1.6 mL/min/
1.73 m2 versus 5.2 mL/min/1.73 m2; p = 0.007) over 36
weeks [52]. LCZ696 had a favorable safety profile similar to
that observed with valsartan.
An outcomes study (Prospective comparison of ARni with
ARB Global Outcomes in heart failure with preserved ejectioNfraction [PARAGON-HF]) is currently planned to determine
whether the promising biomarker results of LCZ696 in
patients with HFpEF will translate into clinical benefit as
measured by cardiovascular mortality and HF hospitaliza-
tions compared with valsartan.
Conclusion and future directions
The NP system has been shown to play an important cardiac
and renal protective role. As a result it has been hypothesized
that enhancing NPs may be beneficial in HF. Neprilysin
inhibition enhances NP levels by reducing their enzymatic
degradation. However, the utility of neprilysin inhibition
requires management of the activation of the RAAS, which
occurs with neprilysin inhibition alone. LCZ696, the firstwww.drugdiscoverytoday.com e137
Drug Discovery Today: Therapeutic Strategies | Heart failure Vol. 9, No. 4 2012ARNI in clinical development, meets this requirement since
the compound enhances the actions of the NP system by
inhibiting neprilysin while concurrently suppressing the
activity of the RAAS by blocking the angiotensin AT1
receptor.
Results from the clinical trial program of LCZ696 show that
LCZ696 improves hemodynamics and cardiorenal biomarkers.
Ongoing studies will determine whether these effects translate
to improvements in outcomes of patients with chronic HF with
either reduced or preserved LVEF. Additional studies of the NPs
and of LCZ696 will be needed to further elucidate the mechan-
isms of its potential cardiorenal protection and the clinical
relevance of the metabolic effects of the NPs.
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